Chinese General Practice ›› 2023, Vol. 26 ›› Issue (36): 4527-4534.DOI: 10.12114/j.issn.1007-9572.2022.0833
Special Issue: 肿瘤最新文章合辑; 肺癌最新文章合辑
• Article • Previous Articles Next Articles
Received:
2022-10-15
Revised:
2023-02-25
Published:
2023-12-20
Online:
2023-05-26
Contact:
CUI Huijuan
通讯作者:
崔慧娟
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0833
临床特征 | 例数 | 百分比(%) | 临床特征 | 例数 | 百分比(%) |
---|---|---|---|---|---|
性别 | 吸烟史 | ||||
男 | 95 | 43.8 | 无 | 164 | 75.6 |
女 | 122 | 56.2 | 轻度 | 8 | 3.7 |
肿瘤部位 | 中度 | 13 | 6.0 | ||
双肺 | 6 | 2.8 | 重度 | 32 | 14.7 |
左肺 | 115 | 39.2 | 饮酒史 | ||
右肺 | 96 | 58.0 | 有 | 31 | 14.3 |
肿瘤分期 | 无 | 186 | 85.7 | ||
Ⅰ期 | 31 | 14.3 | 家族史 | ||
Ⅱ期 | 17 | 7.8 | 有 | 37 | 17.1 |
Ⅲ期 | 24 | 11.1 | 无 | 180 | 82.9 |
Ⅳ期 | 145 | 66.8 | 肿瘤史 | ||
是否手术 | 有 | 23 | 10.6 | ||
是 | 123 | 56.7 | 无 | 194 | 89.4 |
否 | 94 | 43.3 | 肺病史 | ||
胸膜转移 | 有 | 24 | 11.1 | ||
是 | 86 | 39.6 | 无 | 193 | 88.9 |
否 | 131 | 60.4 |
Table 1 Baseline characteristics of 217 NSCLC patients receiving two genetic tests before and after progression
临床特征 | 例数 | 百分比(%) | 临床特征 | 例数 | 百分比(%) |
---|---|---|---|---|---|
性别 | 吸烟史 | ||||
男 | 95 | 43.8 | 无 | 164 | 75.6 |
女 | 122 | 56.2 | 轻度 | 8 | 3.7 |
肿瘤部位 | 中度 | 13 | 6.0 | ||
双肺 | 6 | 2.8 | 重度 | 32 | 14.7 |
左肺 | 115 | 39.2 | 饮酒史 | ||
右肺 | 96 | 58.0 | 有 | 31 | 14.3 |
肿瘤分期 | 无 | 186 | 85.7 | ||
Ⅰ期 | 31 | 14.3 | 家族史 | ||
Ⅱ期 | 17 | 7.8 | 有 | 37 | 17.1 |
Ⅲ期 | 24 | 11.1 | 无 | 180 | 82.9 |
Ⅳ期 | 145 | 66.8 | 肿瘤史 | ||
是否手术 | 有 | 23 | 10.6 | ||
是 | 123 | 56.7 | 无 | 194 | 89.4 |
否 | 94 | 43.3 | 肺病史 | ||
胸膜转移 | 有 | 24 | 11.1 | ||
是 | 86 | 39.6 | 无 | 193 | 88.9 |
否 | 131 | 60.4 |
进展前 | 进展后 | 合计 | |
---|---|---|---|
阴性 | 阳性 | ||
阴性 | 60(27.6) | 10(4.6) | 70(32.3) |
阳性 | 35(16.1) | 112(51.6) | 147(67.7) |
合计 | 95(43.8) | 122(56.2) | 217(100.0) |
Table 2 Comparison of EGFR gene mutations before and after treatment in 217 patients with NSCLC
进展前 | 进展后 | 合计 | |
---|---|---|---|
阴性 | 阳性 | ||
阴性 | 60(27.6) | 10(4.6) | 70(32.3) |
阳性 | 35(16.1) | 112(51.6) | 147(67.7) |
合计 | 95(43.8) | 122(56.2) | 217(100.0) |
突变状态 | PD前 | PD后 | χ2值 | P值 |
---|---|---|---|---|
野生型 | 70(32.3) | 95(43.8) | 6.11 | 0.013 |
突变型 | 147(67.7) | 122(56.2) | 6.11 | 0.013 |
19 DEL | 64(29.5) | 43(19.8) | 5.47 | 0.019 |
21 L858R | 74(34.1) | 52(24.0) | 5.41 | 0.020 |
20 T790M | 2(0.9) | 45(20.7) | 42.10 | <0.001 |
少见突变 | 20(9.2) | 84(38.7) | 51.80 | <0.001 |
Table 3 Distribution of EGFR gene mutations from 217 NSCLC patients before and after treatment
突变状态 | PD前 | PD后 | χ2值 | P值 |
---|---|---|---|---|
野生型 | 70(32.3) | 95(43.8) | 6.11 | 0.013 |
突变型 | 147(67.7) | 122(56.2) | 6.11 | 0.013 |
19 DEL | 64(29.5) | 43(19.8) | 5.47 | 0.019 |
21 L858R | 74(34.1) | 52(24.0) | 5.41 | 0.020 |
20 T790M | 2(0.9) | 45(20.7) | 42.10 | <0.001 |
少见突变 | 20(9.2) | 84(38.7) | 51.80 | <0.001 |
临床特征 | 例数 | 基因清除型组(n=67) | 非基因清除型组(n=150) | χ2值 | P值 | 临床特征 | 例数 | 基因清除型组(n=67) | 非基因清除型组(n=150) | χ2值 | P值 |
---|---|---|---|---|---|---|---|---|---|---|---|
性别 | 2.49 | 0.114 | 家族史 | 0.90 | 0.344 | ||||||
男 | 95 | 24(35.8) | 71(47.3) | 有 | 37 | 9(13.4) | 28(18.7) | ||||
女 | 122 | 43(64.2) | 79(52.7) | 无 | 180 | 58(86.6) | 122(81.3) | ||||
年龄 | 1.09 | 0.297 | 肿瘤史 | 0 | 0.961 | ||||||
<60岁 | 69 | 18(26.9) | 51(34.0) | 有 | 23 | 7(10.4) | 16(10.7) | ||||
≥60岁 | 148 | 49(73.1) | 99(66.0) | 无 | 194 | 60(89.6) | 134(89.3) | ||||
肿瘤部位 | 0.20 | 0.905 | 肺病史 | 4.62 | 0.032 | ||||||
双肺 | 6 | 2(3.0) | 4(2.7) | 有 | 24 | 12(17.9) | 12(8.0) | ||||
左肺 | 115 | 34(50.7) | 81(54.0) | 无 | 193 | 55(82.1) | 138(92.0) | ||||
右肺 | 96 | 31(46.3) | 65(43.3) | 化学治疗 | 0.22 | 0.636 | |||||
肿瘤分期 | 1.00 | 0.318 | 有 | 76 | 25(37.3) | 51(34.0) | |||||
早期(Ⅰ~Ⅱ期) | 48 | 12(17.9) | 36(24.0) | 无 | 141 | 42(62.7) | 99(66.0) | ||||
中晚期(Ⅲ~Ⅳ期) | 169 | 55(82.1) | 114(76.0) | 放射治疗 | 0.04 | 0.848 | |||||
是否手术 | 0.34 | 0.588 | 有 | 26 | 7(10.4) | 17(11.3) | |||||
是 | 123 | 36(53.7) | 87(58.0) | 无 | 191 | 60(89.6) | 133(88.7) | ||||
否 | 94 | 31(46.3) | 63(42.0) | 免疫治疗 | 0 | 0.981 | |||||
胸膜转移 | 3.75 | 0.053 | 有 | 8 | 3(4.5) | 5(3.3) | |||||
是 | 86 | 33(49.2) | 53(35.3) | 无 | 209 | 64(95.5) | 145(96.7) | ||||
否 | 131 | 34(50.8) | 97(64.7) | 靶向治疗 | 11.51 | 0.001 | |||||
吸烟史 | 0.65 | 0.419 | 有 | 139 | 54(80.6) | 85(56.7) | |||||
有 | 172 | 53(79.1) | 111(74.0) | 无 | 78 | 13(19.4) | 65(43.3) | ||||
无 | 45 | 14(20.9) | 39(26.0) | 中医治疗 | 0.03 | 0.860 | |||||
饮酒史 | 0.44 | 0.509 | 有 | 92 | 29(43.3) | 63(42.0) | |||||
有 | 31 | 8(11.9) | 23(15.3) | 无 | 125 | 38(56.7) | 87(58.0) | ||||
无 | 186 | 59(88.1) | 127(84.7) |
Table 4 Clinical characteristics of 217 patients with NSCLC grouped by the prevalence of geneclearance
临床特征 | 例数 | 基因清除型组(n=67) | 非基因清除型组(n=150) | χ2值 | P值 | 临床特征 | 例数 | 基因清除型组(n=67) | 非基因清除型组(n=150) | χ2值 | P值 |
---|---|---|---|---|---|---|---|---|---|---|---|
性别 | 2.49 | 0.114 | 家族史 | 0.90 | 0.344 | ||||||
男 | 95 | 24(35.8) | 71(47.3) | 有 | 37 | 9(13.4) | 28(18.7) | ||||
女 | 122 | 43(64.2) | 79(52.7) | 无 | 180 | 58(86.6) | 122(81.3) | ||||
年龄 | 1.09 | 0.297 | 肿瘤史 | 0 | 0.961 | ||||||
<60岁 | 69 | 18(26.9) | 51(34.0) | 有 | 23 | 7(10.4) | 16(10.7) | ||||
≥60岁 | 148 | 49(73.1) | 99(66.0) | 无 | 194 | 60(89.6) | 134(89.3) | ||||
肿瘤部位 | 0.20 | 0.905 | 肺病史 | 4.62 | 0.032 | ||||||
双肺 | 6 | 2(3.0) | 4(2.7) | 有 | 24 | 12(17.9) | 12(8.0) | ||||
左肺 | 115 | 34(50.7) | 81(54.0) | 无 | 193 | 55(82.1) | 138(92.0) | ||||
右肺 | 96 | 31(46.3) | 65(43.3) | 化学治疗 | 0.22 | 0.636 | |||||
肿瘤分期 | 1.00 | 0.318 | 有 | 76 | 25(37.3) | 51(34.0) | |||||
早期(Ⅰ~Ⅱ期) | 48 | 12(17.9) | 36(24.0) | 无 | 141 | 42(62.7) | 99(66.0) | ||||
中晚期(Ⅲ~Ⅳ期) | 169 | 55(82.1) | 114(76.0) | 放射治疗 | 0.04 | 0.848 | |||||
是否手术 | 0.34 | 0.588 | 有 | 26 | 7(10.4) | 17(11.3) | |||||
是 | 123 | 36(53.7) | 87(58.0) | 无 | 191 | 60(89.6) | 133(88.7) | ||||
否 | 94 | 31(46.3) | 63(42.0) | 免疫治疗 | 0 | 0.981 | |||||
胸膜转移 | 3.75 | 0.053 | 有 | 8 | 3(4.5) | 5(3.3) | |||||
是 | 86 | 33(49.2) | 53(35.3) | 无 | 209 | 64(95.5) | 145(96.7) | ||||
否 | 131 | 34(50.8) | 97(64.7) | 靶向治疗 | 11.51 | 0.001 | |||||
吸烟史 | 0.65 | 0.419 | 有 | 139 | 54(80.6) | 85(56.7) | |||||
有 | 172 | 53(79.1) | 111(74.0) | 无 | 78 | 13(19.4) | 65(43.3) | ||||
无 | 45 | 14(20.9) | 39(26.0) | 中医治疗 | 0.03 | 0.860 | |||||
饮酒史 | 0.44 | 0.509 | 有 | 92 | 29(43.3) | 63(42.0) | |||||
有 | 31 | 8(11.9) | 23(15.3) | 无 | 125 | 38(56.7) | 87(58.0) | ||||
无 | 186 | 59(88.1) | 127(84.7) |
[1] |
|
[2] |
|
[3] |
|
[4] |
吴兆明,刘平,余玲玲,等. 结直肠癌患者循环肿瘤DNA定量KRAS基因突变的检测[J]. 基础医学与临床,2018,38(2):180-184. DOI:10.16352/j.issn.1001-6325.2018.02.007.
|
[5] |
|
[6] |
付光明,刘平,吴芳,等. 一代EGFR-TKIs治疗后进展的晚期NSCLC外周血T790M突变特征[J]. 中华肺部疾病杂志(电子版),2021,14(2):169-173.
|
[7] |
金鹏,冯虎,刘倩倩,等. 早期非小细胞肺癌高复发风险相关基因的生物信息学分析[J]. 中国生物制品学杂志,2018,31(1):35-40. DOI:10.13200/j.cnki.cjb.002050.
|
[8] |
刘平,吴羽华,周立娟,等. 不同基因分型晚期非小细胞肺癌患者的预后分析[J]. 中国肺癌杂志,2017,20(11):741-750. DOI:10.3779/j.issn.1009-3419.2017.11.04.
|
[9] |
中华医学会肿瘤学分会,中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J]. 中华肿瘤杂志,2021,43(6):591-621. DOI:10.3760/cma.j.cn112152-20210207-00118.
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
中华医学会病理学分会,国家病理质控中心,中华医学会肿瘤学分会肺癌学组,等. 非小细胞肺癌分子病理检测临床实践指南(2021版)[J]. 中华病理学杂志,2021,50(4):323-332. DOI:10.3760/cma.j.cn112151-20201220-00945.
|
[17] |
范夷平,杜名,于夫尧,等. 肺癌驱动基因、检测方法及靶向治疗研究进展[J]. 现代肿瘤医学,2020,28(2):330-334.
|
[18] |
|
[19] |
|
[20] |
|
[1] | ZUO Ranran, SUN Suzhen. Clinical Features and Genetic Analysis of Drug-resistant Epilepsy in Children [J]. Chinese General Practice, 2025, 28(06): 756-762. |
[2] | ZHANG Shaotong, WANG Bo, ZHANG Mingrui, MA Guiyan, LIU Shaoguang. Identification of Sepsis Subphenotypes and Risk Stratification Using the Procalcitonin Trajectory [J]. Chinese General Practice, 2025, 28(05): 594-600. |
[3] | DU Huijie, LIU Xingyu, XU Minghuan, YANG Xuezhi, ZHANG Huiqin, MO Jiali, LU Yi, KUANG Jie. Advances in the Prognostic Prediction of Acute Ischemic Stroke: Using Machine Learning Predictive Models as an Example [J]. Chinese General Practice, 2025, 28(05): 554-560. |
[4] | ZHANG Pingshu, XUE Jing, XING Aijun, WANG Lianhui, MA Qian, FU Yongshan, YUAN Xiaodong. Study on Sleep Status and Prognostic Factors in Patients with Acute Posterior Circulation Ischemic Stroke [J]. Chinese General Practice, 2025, 28(05): 548-553. |
[5] | ZHU Lu, AI Jun, LIAO Shengwu, HUANG Shuting, GONG Nirong, KONG Yaozhong, LIU Dehui, DOU Xianrui, ZHANG Guangqing. Association of Prognostic Nutritional Index with Cardiovascular Mortality in Patients with Peritoneal Dialysis: a Multicenter Retrospective Cohort Study [J]. Chinese General Practice, 2025, 28(05): 568-574. |
[6] | ZHANG Shuo, ZHANG Long, ZHANG Yan, LI Jianping. Advances in Molecular Biotechnology for Diagnosing and Treating Familial Hypercholesterolemia [J]. Chinese General Practice, 2024, 27(36): 4498-4504. |
[7] | ZHANG Lianfang, ZHENG Yabin, LIN Xuefeng, XIE Rongcheng, MA Jiefei. Clinical Predictive Value of Immature Platelet Fraction Combined with Other Biomarkers for the Severity and Prognosis of Sepsis [J]. Chinese General Practice, 2024, 27(35): 4417-4425. |
[8] | YI Fen, WANG Yong, XU Aihui. Evaluation Value of Peripheral Absolute Eosinophil Count for the Prognosis of Lung Cancer [J]. Chinese General Practice, 2024, 27(32): 4001-4008. |
[9] | DENG Lin, LU Jun. Mitochondrial DNA Depletion Syndrome Caused by RRM2B Gene Mutation: Clinical Characteristics and Genetic Analysis of Two Cases with Different Types (8A and 8B) [J]. Chinese General Practice, 2024, 27(29): 3704-3708. |
[10] | WANG Wuchao, LIU Siqi, LIU Qianqian, ZHU Jihong. Clinical Characteristics of Acute Pulmonary Embolism Complicated with Thrombocytopenia: a Retrospective Study [J]. Chinese General Practice, 2024, 27(27): 3372-3377. |
[11] | LIU Xingyu, DU Huijie, MO Jiali, XU Minghuan, LIU Zuting, YANG Xuezhi, ZHANG Huiqin, YI Yingping, KUANG Jie. Correlation between Remnant Cholesterol and the Risk of Ischemic Stroke Recurrence and Its Predictive Value [J]. Chinese General Practice, 2024, 27(26): 3227-3231. |
[12] | RAN Zhuorui, SUN Ruixin, JIA Jingyi, CHE Zhaoyu, LI Ruixi, HE Yaping, CHU Qiao. Advances in Life Goal Adjustment Ability of Cancer Patients and Its Effect on Physical and Mental Health [J]. Chinese General Practice, 2024, 27(23): 2822-2828. |
[13] | KANG Yinnan, SHI Jiaqi, WANG Junke, LI Bin, LI Chuyi, MA Jun, YU Xiaohui. Advances in the Application of Antibody Drug Conjugate in Gastric Cancer with Low Expression of Human Epidermal Growth Factor Receptor 2 [J]. Chinese General Practice, 2024, 27(18): 2287-2294. |
[14] | YIN Qiuguo, QIN Xintong, ZHANG Yidan, JIANG Peng, GUO Ping, JIA Xingtai, JIAN Liguo. Correlation between Insulin Resistance Metabolic Score and Poor Prognosis in Patients with Chronic Heart Failure [J]. Chinese General Practice, 2024, 27(18): 2179-2185. |
[15] | MA Guifen, ZHANG Qian, LIU Juan, SUN Jing, LIN Genlai. Risk Factors Analysis of Long-term Prognosis in Patients with D2 Radical Surgery for Stage Ⅲ Gastric Cancer after Adjuvant Chemoradiotherapy: Based on the Data of 10-year Follow-up [J]. Chinese General Practice, 2024, 27(17): 2091-2097. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||